Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Assets for 16 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets changed N/A to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a N/A change, with the full-year FY2025 number at $1.4 billion, changed N/A from a year prior.
  • Assets was $1.4 billion for Q4 2025 at Cytokinetics, down from $1.4 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.5 billion in Q2 2024 to a low of $564.3 million in Q2 2021.
  • A 5-year average of $993.8 million and a median of $856.3 million in 2022 define the central range for Assets.
  • Peak YoY movement for Assets: soared 124.9% in 2021, then plummeted 31.17% in 2023.
  • Cytokinetics' Assets stood at $841.3 million in 2021, then rose by 20.62% to $1.0 billion in 2022, then decreased by 18.77% to $824.3 million in 2023, then surged by 74.21% to $1.4 billion in 2024, then decreased by 0.8% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Assets are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.2 billion (Q2 2025).